NV-387: A Prospective Antiviral for Pediatric Use by NanoViricides

NanoViricides, Inc., a clinical-stage company, has announced positive safety results for its broad-spectrum antiviral NV-387 in a juvenile mouse study. This study is a potential breakthrough, paving the way for pediatric clinical trials targeting serious viral infections like Ebola, Mpox, and Measles, which lack effective treatments.

NV-387 is currently involved in Phase II clinical trials for Ebola and Mpox in the Democratic Republic of Congo. Children, often disproportionally affected by these viruses, could benefit significantly if Phase III trials confirm efficacy. Moreover, NV-387 has received Orphan Drug Designation for Measles, indicating FDA interest due to its unmet medical need status.

The juvenile mouse study highlights NV-387's strong safety profile, with no observed adverse effects at high dosage levels. NanoViricides anticipates expanding its clinical trials to include pediatric cohorts, marking a significant step towards addressing global viral disease challenges in younger populations.